OVID vs LGND

For growth investors, Ovid Therapeutics Inc.

(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 27. 3% for Ligand Pharmaceuticals Incorporated (LGND). Analysts rate Ovid Therapeutics Inc. (OVID) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.

0%, compared to -21. 6% for Ovid Therapeutics Inc. (OVID). Over 10 years, the gap is even starker: LGND returned +73. 0% versus OVID's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus Ovid Therapeutics Inc. 's 1. 45β — meaning OVID is approximately 47% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 1% for Ovid Therapeutics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ovid Therapeutics Inc.

(OVID) is pulling ahead at 1181% versus 27. 3% for Ligand Pharmaceuticals Incorporated (LGND). On earnings-per-share growth, the picture is similar: Ovid Therapeutics Inc. grew EPS 35. 1% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.

4% net margin versus -240. 1% for Ovid Therapeutics Inc. — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at -13. 5% versus -585. 2% for OVID. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OVID: 28.

2% to $3. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

99)). Both have compounded well over 10 years (LGND: +73. 0%, OVID: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.